Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
News about InMode Ltd. (INMD) centers on its role as a global provider of medical technologies based on novel radio frequency (RF) energy, along with its financial performance as a Nasdaq-listed company. Press releases regularly highlight quarterly and annual results, revenue guidance ranges, and commentary from management on market conditions, tariffs, and geopolitical developments affecting its operating environment.
Investors following InMode news will find detailed updates on quarterly revenues, gross margins, operating income, and cash position, often presented alongside non-GAAP metrics that exclude share-based compensation and related tax adjustments. The company also issues announcements when it provides or revises full-year revenue guidance, giving insight into management’s expectations for its RF-based aesthetic and medical device business.
Another key news theme is capital markets and investor relations activity. InMode frequently announces participation in major healthcare and medical technology investor conferences hosted by firms such as UBS, Jefferies, Canaccord Genuity, Baird, and Needham. These items describe fireside chats, formal presentations, and one-on-one investor meetings featuring senior executives, as well as links to live webcasts and replays.
Corporate governance and shareholder matters also appear in the news flow. For example, an external stockholder, DOMA Perpetual Capital Management LLC, publicly released a letter urging InMode’s board to expand capital returns to shareholders, focusing on share repurchases and discussing the company’s cash position and valuation. In addition, InMode has announced leadership changes, such as the appointment of a President of North America, reflecting developments in its organizational structure and regional strategy.
By tracking INMD news, readers can monitor earnings releases, guidance updates, conference participation, shareholder communications, and leadership announcements that together provide a current picture of how InMode presents its business and responds to financial and market dynamics.
DOMA Perpetual Capital Management, a significant stockholder of InMode Ltd. (NYSE: INMD), has sent a letter to the company's Board of Directors demanding two major actions: the immediate resumption of the share repurchase program and the removal of CEO Moshe Mizrahy. The letter criticizes Mizrahy's leadership, citing his misunderstanding of buybacks, poor financial performance, and questionable management decisions.
The investor highlights that InMode currently holds approximately 60% of its market cap in cash ($500 million), with no debt and strong free cash flow exceeding $100 million. With a market cap of just $875 million, DOMA argues the company is severely undervalued, considering its assets include global distribution, extensive installed base, unique IP, and the Morpheus8 brand, while maintaining 80% gross margins.
InMode Ltd. (INMD), a leading provider of innovative medical technologies, has announced its participation in three upcoming investor conferences in May and June 2025:
1. BNP 3rd Annual Aesthetics Day - Virtual fireside chat on May 19 featuring CEO Moshe Mizrahy and CFO Yair Malca
2. Barclays West Coast Bus Trip - In-person investor tour at InMode's North American headquarters in Irvine, CA on May 29, featuring CFO Yair Malca
3. Jefferies Global Healthcare Conference - In-person fireside chat in New York on June 4 with CEO Moshe Mizrahy and CFO Yair Malca
InMode (NASDAQ: INMD) has secured a significant legal victory against counterfeit sellers on DHGate platform. The US District Court for the Central District of California has granted InMode a permanent injunction and damages against defendants selling counterfeit Morpheus8 radio frequency microneedling devices and needle cartridges. The court ruling includes freezing the defendants' assets and halting their product listings.
The decision favors InMode on all claims including trademark infringement, false designation of origin, and California unfair competition. To combat counterfeiting, InMode has launched a Verified Provider Program for Morpheus8, enabling certified clinics to demonstrate their authenticity. Patients can verify authorized providers through InMode's Find a Provider tool at www.inmodemd.com.
InMode (NASDAQ: INMD) reported Q1 2025 financial results showing a 3% year-over-year revenue decline to $77.9 million, compared to $80.3 million in Q1 2024. The company experienced decreased performance metrics across the board:
- Consumables and service revenue decreased 10% YoY
- GAAP operating income was $15.6 million
- Gross margins declined to 78% from 80%
- GAAP net income fell to $18.2 million ($0.26 per share) from $23.7 million ($0.28 per share)
The company completed a share repurchase program in April 2025, buying back 6.95 million shares worth $127 million. Management revised down their 2025 guidance, now expecting revenues between $395-405 million and non-GAAP earnings per diluted share of $1.64-1.68, lower than previous guidance of $1.95-1.99.
InMode (NASDAQ: INMD) has announced its preliminary Q1 2025 financial expectations and upcoming earnings call details. The company anticipates Q1 2025 revenue between $77.2-$77.5 million, with a projected non-GAAP gross margin of 78-79%. InMode has also reiterated its full-year 2025 revenue guidance of $395-405 million.
The company will host its Q1 2025 earnings conference call on April 28, 2025, at 8:30 a.m. Eastern Time, featuring presentations from CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. The call will be accessible via various toll-free numbers and webcast through InMode's website.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's leadership team, including CEO Moshe Mizrahy and CFO Yair Malca, will engage in a fireside chat on April 8, 2025, at 2:15 pm Eastern Time.
The discussion will be moderated by Michael Matson, Senior Equity Analyst. Investors can access a live webcast of the presentation, and the company will also conduct one-on-one meetings with investors during the event. Interested parties seeking to schedule meetings are advised to contact their Needham representative.
InMode (NASDAQ: INMD) has issued a comprehensive response to DOMA Perpetual Capital Management's concerns regarding capital allocation and operational management. CEO Moshe Mizrahy addressed several key points:
The company has returned approximately $500M to shareholders through share repurchases since 2022, buying back nearly 30% of company shares. InMode continues its 10% annual buyback program through 2025 and is exploring additional capital return options.
Regarding operations, InMode maintains three FDA-approved manufacturing facilities, all capable of producing their complete platform range. The company launches two new platforms/indications annually and maintains ten ongoing R&D projects. InMode has recently acquired Viveve's patent portfolio and a University of California patent for SUI.
The company has made acquisition attempts in the injectable sector but continues to seek strategic M&A opportunities that would enhance EPS. InMode emphasizes its commitment to maintaining sufficient cash reserves for future opportunities while ensuring efficient capital allocation.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in two major investor conferences in March 2025:
- Barclays 27th Annual Global Healthcare Conference on March 12 at 9:00 am EDT in Miami, FL, featuring CFO Yair Malca in a fireside chat moderated by Senior Equity Analyst Matt Miksic
- Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 18 at 9:20 am EDT, featuring CEO Moshe Mizrahy and CFO Yair Malca in a virtual fireside chat moderated by Senior Equity Analyst Suraj Kalia
Both events will include one-on-one meetings and offer live webcasts of the presentations.
InMode (NASDAQ: INMD) reported Q4 2024 revenues of $97.9 million, down 23% from Q4 2023, and full-year 2024 revenues of $394.8 million, representing a 20% year-over-year decrease. The company's Q4 GAAP net income was $82.8 million ($1.14 per share), while non-GAAP net income was $31.1 million ($0.42 per share).
The company returned $285.4 million to shareholders through share repurchases in 2024, representing approximately 19% of share capital. The Board approved a new 10% share repurchase program, which combined with 2024 buybacks, represents about 27% of shares outstanding within a 15-month timeframe.
For 2025, InMode projects revenues between $395-405 million, with non-GAAP earnings per diluted share expected between $1.95-1.99. The company maintains a strong cash position of $596.5 million as of December 31, 2024.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference. The event will take place in Snowbird, Utah on Wednesday, February 12, 2025.
The company's Chief Financial Officer, Yair Malca, will be available for investor meetings during the conference. Interested investors can arrange meetings through their BTIG sales representatives. Additional information about the event can be accessed through InMode's investor relations website.